Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Declines By 19.0%

iTeos Therapeutics, Inc. (NASDAQ:ITOS) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 1,280,000 shares, a decrease of 19.0% from the February 13th total of 1,580,000 shares. Approximately 3.9% of the shares of the company are sold short. Based on an average trading volume of 362,400 shares, the days-to-cover ratio is presently 3.5 days.

Analyst Upgrades and Downgrades

ITOS has been the topic of a number of recent research reports. JPMorgan Chase & Co. cut their target price on shares of iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th. Wells Fargo & Company dropped their price objective on shares of iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, March 6th. Wedbush reiterated an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. Finally, HC Wainwright restated a “buy” rating and issued a $46.00 price target on shares of iTeos Therapeutics in a research report on Thursday, March 6th.

Institutional Investors Weigh In On iTeos Therapeutics

Several institutional investors have recently made changes to their positions in ITOS. Point72 DIFC Ltd acquired a new stake in shares of iTeos Therapeutics in the third quarter valued at about $31,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in iTeos Therapeutics in the fourth quarter valued at about $42,000. Virtus ETF Advisers LLC lifted its position in shares of iTeos Therapeutics by 58.2% during the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company’s stock valued at $69,000 after acquiring an additional 3,293 shares during the period. Forefront Analytics LLC purchased a new stake in shares of iTeos Therapeutics during the 4th quarter worth approximately $85,000. Finally, Graham Capital Management L.P. acquired a new stake in shares of iTeos Therapeutics in the 4th quarter worth approximately $85,000. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

iTeos Therapeutics Price Performance

Shares of ITOS stock traded down $0.27 during mid-day trading on Tuesday, hitting $7.09. The stock had a trading volume of 401,566 shares, compared to its average volume of 457,405. The firm has a market cap of $270.80 million, a PE ratio of -2.25 and a beta of 1.38. The company’s 50-day simple moving average is $7.46 and its 200-day simple moving average is $8.93. iTeos Therapeutics has a fifty-two week low of $6.67 and a fifty-two week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last released its earnings results on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.13. On average, analysts expect that iTeos Therapeutics will post -3.49 EPS for the current year.

About iTeos Therapeutics

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.